Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo

Circulation Research

Volumn 82, Issue 2, 1998, Pages 147-156

  Yonemitsu, Yoshikazu ^a,d   Kaneda, Yasufumi ^c   Tanaka, Shinji ^b   Nakashima, Yutaka ^a   Komori, Kimihiro ^a   Sugimachi, Keizo ^a   Sueishi, Katsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HARVARD MEDICAL SCHOOL   (United States)

^c OSAKA UNIVERSITY   (Japan)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Apoptosis; Cell cycle arrest; Hemagglutinating virus of Japan liposome; Smooth muscle; Wild type p53

Indexed keywords

PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; CATTLE; CELL PROLIFERATION; DNA SYNTHESIS; ELECTRON MICROSCOPY; FLOW CYTOMETRY; GENE TARGETING; GROWTH INHIBITION; GROWTH REGULATION; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VASCULAR SMOOTH MUSCLE;

EID: 0032498613     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.82.2.147     Document Type: Article

References (32)

1. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
2. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-816.
3. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res, 1994;211:90-98.
4. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxity of anticancer agents. Cell. 1993;74:957-967.
5. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, Epstein SE. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994;265:391-394.
6. Sarac TP, Riggs PN, Williams JP, Feins RH, Baggs R, Rubin P, Green RM. The effects of low-dose radiation on neointimal hyperplasia. J Vasc Surg. 1995;22:17-24.
7. Waksman R, Robinson KA, Crocket IR, Gravanis MB, Palmer SJ, Wang C, Cipolla GD, King SB III. Intracoronary radiation before stent implantation inhibits neointimal formation in stented porcine coronary arteries. Circulation. 1995;92:1383-1386.
8. Hehrlein C, Gollan C, Donges K, Metz J, Reissen R, Fehsenfeld P, von Hodenberg E, Kuber W. Low-dose radioactive endovascular stents prevent smooth muscle cell proliferation and neointimal hyperplasia in rabbits. Circulation. 1995;92:1570-1575.
9. Kaneda Y, Uchida T, Kim J, Ishiura M, Okada Y. The improved efficient method for introducing macromolecules into cells using HVJ (Sendai virus) liposomes with gangliosides. Exp Cell Res. 1987;173:56-69.
10. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science. 1989;243:375-378.
11. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Novel intraluminal molecular delivery of antisense cdc2 kinase and PCNA oligonucleotide results in chronic inhibition of neointimal hyperplasia. Prof Natl Acad Sci U S A. 1993;90:8474-8478.
12. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994;93:1458-1469.
13. Yonemitsu Y, Kaneda Y, Morishita R, Nakagawa K, Nakashima Y, Sueishi K. Characterization of in vivo gene transfer into the arterial wall mediated by the HVJ (Sendai virus)-liposomes: an effective tool for the in vivo study of arterial diseases. Lab Invest. 1996;75:313-323.
14. Chomazynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
15. Borenfreund E, Babich H, Martin-Aleguacil N. Rapid chemosensitivity assay with human normal and tumor cells in vitro. In Vitro Cell Dev Biol. 1990;26:1030-1034.
16. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest. 1983;49:208-215.
17. Bennett MR, Evan GI, Schwartz SM. Apoptosis of rat vascular smooth muscle cells in regulated by p53-dependent and -independent pathways. Circ Res. 1995;77:266-273.
18. Soussi T, Caron de Fromentel C, Breugnot C, May E. Nudeotide sequence of a cDNA encoding the rat p53 oncoprotein. Nucleic Acids Res. 1988;16:11384. Letter.
19. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304-6311.
20. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A. 1992;89:7491-7495.
21. Stewart N, Hicks GG, Paraskevas F, Mowat M. Evidence for a second cell cycle block at G2/M by p53. Oncogens. 1995;10:109-115.
22. Katayose D, Wersto R, Cowan K, Seth P. Consequences of p53 gene expression by adenovirus vector on cell cycle arrest and apoptosis in human aortic vascular smooth muscle cells. Biochem Biophys Res Commun. 1995;215:446-451.
23. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci U S A. 1996;93:11848-11852.
24. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet. 1992;1:45-49.
25. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21, inhibits vascular smooth muscle cell proliferation and neointimal formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96:2260-2268.
26. Jackson CL, Raines EW, Ross R, Reidy MA. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb. 1993;13:1218-1226.
27. Kunz C, Pebler S, Otte J, von der Ahe D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res. 1995;23:3710-3717.
28. Ginsberg D, Mechta F, Yaniv M, Oren M. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A. 1991;88:9979-9983.
29. Santhanam U, Ray A, Sehgal PB. Repression of the interleukin-6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Nad Acad Sci U S A. 1991;88:7605-7609.
30. Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN, Schwartz SM. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol. 1990;111:2149-2158.
31. Kim S, Kawamura M, Wanibuchi H, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Iwao H. Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery. Circulation 1995;92:88-95.
32. Feldman LJ, Steg PG, Zheng LP, Chen D, Kearney M, McGarr SE, Barry JJ, Delieu J-F, Perricaudet M, Isner JM. Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit. J Clin Invest. 1995;95:2662-2671.